Jerel Davis is a Partner based in Vancouver. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics, Laguna Pharmaceuticals and several of the Inception Sciences discovery start-ups. He has also led Versant’s execution of build-to-buy structured acquisitions with Celgene, Roche and Bayer. Over the last few years, Jerel has focused on establishing Versant’s presence in Canada, including the launch of new companies in Vancouver, Toronto and Montreal. Prior to joining Versant, Jerel was Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical device and molecular diagnostics. He has worked in a number of healthcare markets globally including the US, Europe, China, Russia and India. Jerel was a post doctoral researcher at Stanford University until 2005 and in research at Amgen from 1999-2000.
- Sarah Cross